Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763990 | 0.99 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10HTTHDAC3 | |
| SCHEMBL6709497 | 0.97 | KDM4E (0.47) | KDM4EALDH1A1HSD17B10HTTPDE5A | |
| SCHEMBL6709456 | 0.93 | KDM4E (0.48) | KDM4EALDH1A1HSD17B10HTTPDE5A | |
| SCHEMBL6707067 | 0.92 | ALDH1A1 (0.42) | KDM4EALDH1A1HSD17B10HTTHDAC3 | |
| SCHEMBL6707030 | 0.91 | ALDH1A1 (0.42) | KDM4EALDH1A1HSD17B10HTTPDE5A | |
| SCHEMBL7662381 | 0.91 | HDAC3 (0.42) | KDM4EALDH1A1HTTHDAC3HDAC1 | |
| SCHEMBL6706621 | 0.90 | POLB (0.43) | KDM4EALDH1A1HTTHDAC3HDAC1 | |
| SCHEMBL6707039 | 0.89 | PDE4A (0.44) | KDM4EALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL6709515 | 0.88 | ALDH1A1 (0.43) | KDM4EALDH1A1HSD17B10HTTPDE5A | |
| SCHEMBL6706619 | 0.88 | PDE4A (0.44) | KDM4EALDH1A1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040072846-A1 | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | US | disclosed |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040034040-A1 | Use of thienopyrimidines | MERCK PATENT GMBH (DE) | 2004-02-19 | — | — | US | disclosed |
| EP-1357915-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
| EP-1355649-A2 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO 4,3-D]PYRIMIDINE AND NITRATES OR THIENOPYRIMIDINES AND NITRATES | MERCK PATENT GmbH (DE) | 2003-10-29 | — | — | EP | disclosed |
| EP-1337256-A2 | USE OF THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002062343-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002060449-A2 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO[4,3-D]PYRIMIDINE AND NITRATES OR THIENOPYRIMIDINES AND NITRATES | MERCK PATENT GMBH (DE) | 2002-08-08 | — | — | WO | disclosed |
| WO-2002041896-A2 | USE OF THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | PTGIS, DPYD, PTGIR | KDM4E 3713/4885ALDH1A1 1785/4885HSD17B10 3503/4885 |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | EDNRA, EDNRB, PTGIR | KDM4E 2219/4885ALDH1A1 3483/4885HSD17B10 3904/4885 |
| US-20040034040-A1 | Use of thienopyrimidines | DPYD, TBXAS1, TYMS | KDM4E 4364/4885ALDH1A1 497/4885HSD17B10 2736/4885 |
| US-20040072846-A1 | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives | PTGER1, TBXA2R, PTGIS | KDM4E 4709/4885ALDH1A1 2919/4885HSD17B10 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.